Description
Summary Abstract
DSIP (Delta Sleep-Inducing Peptide; Deltaran; WAGGDASGE) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated in 1974 by Schoenenberger and Monnier from rabbit cerebral venous blood during sleep induction. Despite five decades of research, DSIP remains an “orphan peptide” — no dedicated biosynthetic gene has been identified and the primary receptor has not been cloned. It crosses the blood–brain barrier (BBB) via both passive transmembrane diffusion and a saturable, carrier-mediated choroid plexus transport system (Kt ≈ 5.0 nM). The pharmacological profile encompasses modulation of sleep architecture, HPA axis suppression, NMDA receptor antagonism, GABAergic potentiation, and antioxidant enzyme upregulation. DSIP exhibits a bell-shaped dose-response curve: nanomolar-to-microgram doses promote sleep and sedation; milligram-range doses produce paradoxical wakefulness in some models. A 107-patient clinical study showed marked improvement in 87% of alcohol withdrawal and 97% of opiate withdrawal cases. Deltaran preclinical murine studies documented a 2.6-fold reduction in spontaneous tumor incidence and +24.1% maximum lifespan. The FDA has placed DSIP on its significant safety risks list for compounded preparations due to immunogenicity concerns.
Clinical Indications
DSIP has generated clinical and preclinical evidence across sleep medicine, addiction medicine, longevity research, and neuroprotection:
- Substance Withdrawal: 107-patient clinical study: marked improvement in 87% of alcohol withdrawal and 97% of opiate withdrawal cases; mechanistic basis: NMDA modulation, GABAergic enhancement, HPA normalization, and opioid receptor resensitization.
- Sleep Architecture: Double-blind, placebo-controlled insomnia trial demonstrated improved sleep efficiency, reduced onset latency, and preserved daytime alertness; unlike benzodiazepines, DSIP at therapeutic doses does not suppress REM sleep or produce rebound insomnia in published trial data.
- Longevity & Oncology (Preclinical): Deltaran murine studies: 2.6-fold reduction in spontaneous tumor incidence, +24.1% maximum lifespan; proposed mechanisms include mitochondrial respiration enhancement, antioxidant enzyme upregulation (SOD, catalase, GPx), and NF-κB/AP-1 suppression via GILZ-homologous activity.
- Neuroprotection & HPA Research: DSIP’s NMDA antagonism and HPA suppression make it a useful probe in models of excitotoxicity, chronic stress-driven neuroinflammation, and glucocorticoid dysregulation.
Contraindications
- FDA Immunogenicity Risk: The FDA has placed DSIP on its significant safety risks list for compounded preparations; subjects may develop anti-DSIP antibodies with theoretical cross-reactivity against endogenous GILZ/TSC22 domain proteins; this regulatory designation warrants careful informed consent and protocol monitoring in clinical research settings.
- Concurrent CNS Depressants: DSIP potentiates CNS depressants including benzodiazepines and alcohol via synergistic GABAergic and NMDA effects; combination with opioids carries additive risk — particularly relevant to withdrawal research protocols that include these compound classes.
- Milligram-Range Dosing: Paradoxical stimulatory and wake-promoting effects have been documented at milligram-range doses in animal models; linear dose escalation does not apply — protocols must specify doses within the established pharmacological window.
Mechanism of Action (MOA)
DSIP acts through several mechanistically distinct but overlapping pathways, without a single characterized primary receptor:
NMDA & GABAergic Modulation
DSIP antagonizes or modulates NMDA glutamate receptor activity, reducing calcium influx and limiting excitotoxic cascades — relevant to neuroprotection, sedation, and withdrawal-driven neuronal hyperexcitability. Concurrently, DSIP enhances GABAergic inhibitory tone, contributing to sleep-promoting, anxiolytic, and anticonvulsant effects observed at low doses.
HPA Axis & Opioid Receptor Modulation
DSIP suppresses CRH-driven ACTH release and downstream cortisol production, normalizing HPA axis hyperactivation. It also modulates mu-opioid receptor responsiveness, potentially through receptor resensitization — a mechanism that may explain its utility in attenuating opioid and alcohol withdrawal syndromes.
Mitochondrial & Antioxidant Upregulation
DSIP enhances mitochondrial respiration and upregulates antioxidant enzymes including superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx). These mechanisms may underlie the lifespan extension and tumor-incidence reduction observed in the Deltaran murine chronic-administration studies.
GILZ/TSC22 Transcriptional Homology
DSIP shares structural homology with glucocorticoid-induced leucine zipper (GILZ) proteins; this domain is associated with transcriptional modulation of AP-1 and NF-κB — anti-inflammatory regulatory pathways that may explain the peptide’s broad CNS pharmacological profile and its immunological considerations.
Key Features & Specifications
DSIP is a small, water-soluble nonapeptide with confirmed BBB penetration and a unique bell-shaped pharmacology:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE) |
| CAS Number | 62568-57-4 |
| Molecular Formula | C35H48N10O15 |
| Molecular Weight | ~849 Da |
| PubChem CID | 68807 |
| Synonyms | DSIP; Delta Sleep-Inducing Peptide; Deltaran; WAGGDASGE |
| Form / Variation | 5 MG Lyophilized (P-008, $35) |
Storage, Safety, and Handling
Storage Protocol
Lyophilized DSIP should be stored at −20°C, protected from light and moisture; under these conditions the lyophilized form is stable for up to 24 months. After reconstitution with sterile water for injection (gentle inversion — avoid vortexing), the solution must be used within 24 hours and stored at 2–8°C; do not refreeze reconstituted material. The in vitro serum half-life of DSIP is approximately 15 minutes due to rapid proteolytic degradation; maintain the cold chain from storage through preparation to minimize pre-experimental peptide loss.
Handling & Compliance
Standard aseptic technique and appropriate PPE (gloves, eye protection) are required during reconstitution and handling. The FDA has placed DSIP on the significant safety risks list for compounded preparations based on documented immunogenicity; anti-DSIP antibody formation has been reported and the possibility of cross-reactivity with endogenous GILZ/TSC22 domain proteins warrants monitoring in clinical research protocols. DSIP is not currently listed on the WADA Prohibited List; researchers working in anti-doping contexts should verify current status directly with WADA.